疑似他汀类药物不良反应:湖北省2014-2022年自发报告分析

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Haochengyi Wang, Hongyu Bi, Xiaofang Shangguan, Zherui Chen, Rui Huang, Xianglong Chen, Yuanxuan Cai
{"title":"疑似他汀类药物不良反应:湖北省2014-2022年自发报告分析","authors":"Haochengyi Wang, Hongyu Bi, Xiaofang Shangguan, Zherui Chen, Rui Huang, Xianglong Chen, Yuanxuan Cai","doi":"10.1080/14740338.2025.2536343","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Statins, some of the most widely prescribed medications for the treatment of cardiovascular diseases, cause common and serious adverse drug reactions (ADRs). However, studies of statin-related ADRs in the Chinese population are lacking.</p><p><strong>Research design and methods: </strong>ADR reports of statins collected by the Hubei Adverse Drug Reaction Monitoring Center from 2014 to 2022 were analyzed. Statin safety was described using descriptive analysis and three signal mining methods: reporting odds ratio, proportional reporting ratio, and a combined standard method.</p><p><strong>Results: </strong>ADRs were common in individuals aged 50-79 years. Most administration routes are oral. ADR reports of atorvastatin and rosuvastatin were numerous and serious. The reports mainly consisted of gastrointestinal disorders, hepatobiliary disorders. Three signal mining algorithms generated 91 identical drug - event combination signals, including 23 off-label ADRs.</p><p><strong>Conclusions: </strong>Atorvastatin was associated with a higher number of ADR reports and a higher proportion of serious ADRs than the other statins. Atorvastatin may cause off-label ADRs such as back pain, increased blood bilirubin, bone pain, hemorrhage, hepatic failure, and hepatocellular injury. Drug instructions should be enriched for better labeling of ADRs.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-8"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Suspected statin-related adverse drug reactions: analysis of spontaneous reports in Hubei Province, China (2014-2022).\",\"authors\":\"Haochengyi Wang, Hongyu Bi, Xiaofang Shangguan, Zherui Chen, Rui Huang, Xianglong Chen, Yuanxuan Cai\",\"doi\":\"10.1080/14740338.2025.2536343\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Statins, some of the most widely prescribed medications for the treatment of cardiovascular diseases, cause common and serious adverse drug reactions (ADRs). However, studies of statin-related ADRs in the Chinese population are lacking.</p><p><strong>Research design and methods: </strong>ADR reports of statins collected by the Hubei Adverse Drug Reaction Monitoring Center from 2014 to 2022 were analyzed. Statin safety was described using descriptive analysis and three signal mining methods: reporting odds ratio, proportional reporting ratio, and a combined standard method.</p><p><strong>Results: </strong>ADRs were common in individuals aged 50-79 years. Most administration routes are oral. ADR reports of atorvastatin and rosuvastatin were numerous and serious. The reports mainly consisted of gastrointestinal disorders, hepatobiliary disorders. Three signal mining algorithms generated 91 identical drug - event combination signals, including 23 off-label ADRs.</p><p><strong>Conclusions: </strong>Atorvastatin was associated with a higher number of ADR reports and a higher proportion of serious ADRs than the other statins. Atorvastatin may cause off-label ADRs such as back pain, increased blood bilirubin, bone pain, hemorrhage, hepatic failure, and hepatocellular injury. Drug instructions should be enriched for better labeling of ADRs.</p>\",\"PeriodicalId\":12232,\"journal\":{\"name\":\"Expert Opinion on Drug Safety\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14740338.2025.2536343\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2025.2536343","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

他汀类药物是治疗心血管疾病最广泛使用的药物之一,可引起常见和严重的药物不良反应(adr)。然而,中国人群中他汀类药物相关不良反应的研究缺乏。研究设计与方法:对湖北省药品不良反应监测中心2014 - 2022年收集的他汀类药物不良反应报告进行分析。使用描述性分析和三种信号挖掘方法:报告优势比、比例报告比和组合标准方法来描述他汀类药物的安全性。结果:不良反应常见于50 ~ 79岁人群。大多数给药途径是口服的。阿托伐他汀和瑞舒伐他汀不良反应报告多且严重。报告主要包括胃肠疾病、肝胆疾病。三种信号挖掘算法产生91个相同的药物事件组合信号,包括23个标签外adr。结论:与其他他汀类药物相比,阿托伐他汀与更高数量的不良反应报告和更高比例的严重不良反应相关。阿托伐他汀可能引起标签外不良反应,如背痛、血胆红素升高、骨痛、出血、肝功能衰竭和肝细胞损伤。应充实药品说明书,以便更好地标示不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Suspected statin-related adverse drug reactions: analysis of spontaneous reports in Hubei Province, China (2014-2022).

Introduction: Statins, some of the most widely prescribed medications for the treatment of cardiovascular diseases, cause common and serious adverse drug reactions (ADRs). However, studies of statin-related ADRs in the Chinese population are lacking.

Research design and methods: ADR reports of statins collected by the Hubei Adverse Drug Reaction Monitoring Center from 2014 to 2022 were analyzed. Statin safety was described using descriptive analysis and three signal mining methods: reporting odds ratio, proportional reporting ratio, and a combined standard method.

Results: ADRs were common in individuals aged 50-79 years. Most administration routes are oral. ADR reports of atorvastatin and rosuvastatin were numerous and serious. The reports mainly consisted of gastrointestinal disorders, hepatobiliary disorders. Three signal mining algorithms generated 91 identical drug - event combination signals, including 23 off-label ADRs.

Conclusions: Atorvastatin was associated with a higher number of ADR reports and a higher proportion of serious ADRs than the other statins. Atorvastatin may cause off-label ADRs such as back pain, increased blood bilirubin, bone pain, hemorrhage, hepatic failure, and hepatocellular injury. Drug instructions should be enriched for better labeling of ADRs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信